Broyhill **** et Management, a Charlotte-based firm, issued its second-quarter 2026 investor letter, which is available for download here. The Broyhill Equity Composite gained 8.8% in Q2, trailing the MSCI All Country World Index's 15.1% and the MSCI ACWI Value Index's 10.8%. For the first half, the Composite returned 2.3%, versus 11.5% for the Index. The letter highlights that a significant portion of the shortfall occurred in April due to market dynamics and geopolitical events, with tech, particularly semiconductors, driving recent gains. Broyhill notes its lack of direct semiconductor exposure but acknowledges potential interest in the sector if opportunities arise, maintaining its investment philosophy focused on capital protection in fragile market conditions. Also, check the fund's top five holdings to see its best picks in 2026.
In its second-quarter 2026 investor letter, Broyhill **** et Management highlighted IQVIA Holdings Inc. (NYSE:IQV). IQVIA Holdings Inc. (NYSE:IQV) is a US-based provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries. On September 14, 2026, IQVIA Holdings Inc. (NYSE:IQV) closed at $265.67 per share. Over the past month, IQVIA Holdings Inc. (NYSE:IQV) returned 10.68%, and its shares are up 42.21% over the past year. IQVIA Holdings Inc. (NYSE:IQV) has a market capitalization of $43.73 billion, and its stock has traded within a 52-week range of $154.50 to $271.80.
Broyhill **** et Management stated the following regarding IQVIA Holdings Inc. (NYSE:IQV) in its Q2 2026 investor letter:
"IQVIA Holdings Inc. (NYSE:IQV) gained 14% after being our largest detractor in the first quarter. We set out our full case last quarter and will not repeat it here. The second quarter added evidence: results came in ahead, and request-for-proposal flow and award timing both improved. We trimmed the position in June and rolled the proceeds into Thermo Fisher, an exercise in portfolio management rather than a statement about our conviction."
IQVIA Holdings Inc. (NYSE:IQV) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. According to our database, 58 hedge fund portfolios held IQVIA Holdings Inc. (NYSE:IQV) at the end of the second quarter, down from 64 in the previous quarter. While we acknowledge the potential of IQVIA Holdings Inc. (NYSE:IQV) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

#iqvia

Broyhill **** et Management, a Charlotte-based firm, issued its second-quarter 2026 investor letter, which is available for download here. The Broyhill Equity Composite gained 8.8% in Q2, trailing the MSCI All Country World Index's 15.1% and the MSCI ACWI Value Index's 10.8%. For the first half, the Composite returned 2.3%, versus 11.5% for the Index. The letter highlights that a significant portion of the shortfall occurred in April due to market dynamics and geopolitical events, with tech, particularly semiconductors, driving recent gains. Broyhill notes its lack of direct semiconductor exposure but acknowledges potential interest in the sector if opportunities arise, maintaining its investment philosophy focused on capital protection in fragile market conditions. Also, check the fund's top five holdings to see its best picks in 2026.
In its second-quarter 2026 investor letter, Broyhill **** et Management highlighted IQVIA Holdings Inc. (NYSE:IQV). IQVIA Holdings Inc. (NYSE:IQV) is a US-based provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries. On September 14, 2026, IQVIA Holdings Inc. (NYSE:IQV) closed at $265.67 per share. Over the past month, IQVIA Holdings Inc. (NYSE:IQV) returned 10.68%, and its shares are up 42.21% over the past year. IQVIA Holdings Inc. (NYSE:IQV) has a market capitalization of $43.73 billion, and its stock has traded within a 52-week range of $154.50 to $271.80.
Broyhill **** et Management stated the following regarding IQVIA Holdings Inc. (NYSE:IQV) in its Q2 2026 investor letter:
"IQVIA Holdings Inc. (NYSE:IQV) gained 14% after being our largest detractor in the first quarter. We set out our full case last quarter and will not repeat it here. The second quarter added evidence: results came in ahead, and request-for-proposal flow and award timing both improved. We trimmed the position in June and rolled the proceeds into Thermo Fisher, an exercise in portfolio management rather than a statement about our conviction."
IQVIA Holdings Inc. (NYSE:IQV) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. According to our database, 58 hedge fund portfolios held IQVIA Holdings Inc. (NYSE:IQV) at the end of the second quarter, down from 64 in the previous quarter. While we acknowledge the potential of IQVIA Holdings Inc. (NYSE:IQV) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

#holdings #letter #investor

Sept 14 - Novo Nordisk is changing its day-to-day name to 'Novo', and taking a ‌new approach to company culture as it ‌looks to claw back ground in the fierce obesity drug race, the Danish drugmaker said on Monday.
• Novo, which is slated to unveil details on its business strategy during a Capital Markets Day on ‌September 21, will ⁠keep 'Novo Nordisk A/S' as its legal name.
• The company set out on ⁠Monday a new cultural strategy it called "The Novo Way", centred around four principles — customer obsession, competitiveness, clarity, and care and integrity.
• The move comes as ‌it faces fierce competition from rival weight-loss drug maker Eli Lilly, investor pressure to deliver new blockbusters, and setbacks to its medicine pipeline.
• The company's Copenhagen shares are down nearly 15% ‌this year, even as its oral GLP-1 outpaces Eli Lilly by hundreds of thousands of U.S. prescriptions per ‌week, according to IQVIA data provided by an ****** yst.

#novo #company #fierce

Durham, North Carolina-based IQVIA Holdings Inc. (IQV) provides healthcare research services. Valued at $42.3 billion by market cap, the company offers ******* ytics, technology solutions, and clinical research services to the life sciences industry which helps them in the clinical development and commercialization of medical treatments that improve healthcare outcomes for patients.
Companies worth $10 billion or more are generally described as "large-cap stocks," and IQV perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the diagnostics & research industry. With strong revenue growth and a global presence in over 100 countries, IQVIA's expertise and scale provide a competitive edge that is hard to replicate.
'Not Tens Of Billions, But Tens Of Trillions': Nvidia CEO Jensen Huang Says AI Is Like the New Electricity and the Scale Is Unlike Any Tech in History
What It Means for MSFT Stock Investors as Microsoft Switches to 2 Business Segments
RKLB Stock Jumps as Rocket Lab Debuts New Solar Cell for ******* e

#Research #Stock #healthcare

The global healthcare ecosystem in 2026 is leading to a strong recovery in clinical research, with global pharma R&D investment topping $250 billion and the clinical research organization (CRO) market rising to $72 billion at roughly a 9% annual pace. As biopharma companies move capital into complex biologic pipelines, AI-powered trial improvement, and practical data ******* ysis, outsourcing fervor grows. For industry leaders such as IQVIA Holdings Inc. (NYSE:IQV), this macro environment provides structural tailwinds, allowing scaled global operators to grab high-margin clinical trial operations and lock in multi-year backlog visibility.
IQVIA Holdings Inc. (NYSE:IQV) proved the extent of its operational recovery in its second-quarter 2026 results on July 29, exceeding the upper end of its internal guidance across all main financial indicators and driving an 8.8% pre-market share jump. Total revenue was $4.368 billion, increasing 8.7% year-over-year, exceeding ******* yst estimates, while adjusted diluted earnings per share increased 12.1% year-over-year to $3.15, beating consensus projections of $3.02 to $3.06 by a significant margin. At the same time, adjusted EBITDA increased by 9.2% to $994 million, sustaining a 22.8% margin.
While headline earnings and revenue were solid, the true source of the market's optimism was an impressive spike in clinical bookings. IQVIA's core Research & Development Solutions division recorded record net new bookings of $3.15 billion, up 19% year-over-year, with a strong book-to-bill ratio of 1.22x. Trailing-twelve-month bookings increased 13% to $11.3 billion, bringing the total contracted backlog to a record $34.2 billion. Management anticipates that $9.2 billion of this backlog will be converted into recognized revenue during the coming twelve months.
IQVIA Holdings Inc. (NYSE:IQV) raised its full-year financial guidance for 2026 in response to record backlog visibility. Full-year sales are now expected to range between $17.275 billion and $17.475 billion, with adjusted EBITDA rising to $4.0-$4.05 billion and adjusted EPS targeting $12.80-$13. The new projection includes a 100 basis point improvement in organic growth estimates, as well as M&A contributions, while full-year EBITDA margins are expected to remain unchanged at around 23.2% as internal efficiency measures absorb pass-through cost friction. Operating cash flow also increased 26% year-over-year to $558 million, while free cash flow grew 23.3% to $360 million during the quarter.

#holdings #increased

Shares of Iqvia (IQV) surged past a buy point Tuesday after the provider of clinical research services beat second-quarter estimates and raised guidance.
Revenue climbed 8.7% to $4.368 billion year over year, while adjusted earnings increased 12% to $3.15 a share. ****** ysts, on average, expected revenue of $4.310 billion. The consensus earnings estimate was $3.03 per share, with the highest estimate at $3.08, according to FactSet.
Second-quarter new bookings rose 19% to $3.15 billion. The backlog for its Research & Development Solutions business (which handles clinical trials) was $34.2 billion. Iqvia expects that about $9.2 billion of it will convert to revenue over the next 12 months.
Citing improved organic revenue growth, the company raised full-year revenue guidance to $17.275 billion-$17.475 billion, an increase of 6.5% at the midpoint. It had earlier forecast a 5.8% increase. The new guidance ****** umes about 200 basis points from acquisitions vs. 150 basis points in the previous guidance. It expects a smaller tailwind from foreign exchange than before.
Durham, N.C.-based Iqvia also forecast adjusted EPS of $12.80 to $13 for 2026. The previous guidance was $12.65 to $12.95.

#second #clinical #quarter #raised

Our ******* ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Organic revenue growth accelerated to 6% year-over-year, tripling the rate from the prior year due to improving market conditions and strong operational execution.
The R&D Solutions segment benefited from a consistently improving demand environment and higher win rates, particularly within the Emerging Biopharma (EBP) segment which now represents 70% of global clinical trial starts.
Commercial Solutions growth was fueled by a 45% increase in new drug launches in the first half of 2026, driving demand for ******* ytics, consulting, and patient solutions.
Management highlighted a strategic shift in large pharma toward outsourcing full commercialization of therapies in select geographies, where IQVIA is capturing significant market share.

#year #segment #NVIDIA #tell

Artisan Partners, an investment management firm, issued its first-quarter 2026 investor letter for the "Artisan Mid Cap Value Fund". A copy of this letter is available for download here. In Q1 2026, the portfolio underperformed the benchmark Russell Midcap Value Index as the market favored momentum-driven stocks over quality factors. Some holdings faced company-specific setbacks and negative sentiment. The Fund's Investor Class: ARTQX returned -4.93%, Advisor Class: APDQX declined by -4.90%, and Institutional Class: APHQX fell by -4.97%, all trailing the Index's 3.68% gain. The equity market in the quarter was mixed, with mid- and small-cap indices showing resilience despite lagging large-cap growth stocks. Volatility increased, initially fueled by interest in AI and private credit, but escalated after the outbreak of war in Iran, leading to rising oil prices. Sector performance varied, with energy leading the gains. The Fund continues to seek companies capable of value growth during market dislocations at attractive entry points. Also, review the Fund's top five holdings to see its best picks for 2026.
In its first-quarter 2026 investor letter, Artisan Mid Cap Value Fund highlighted Brown & Brown, Inc. (NYSE:BRO) as a newly added position. Brown & Brown, Inc. (NYSE:BRO) is a leading insurance brokerage firm that operates through Retail and Specialty Distribution segments. On July 7, 2026, Brown & Brown, Inc. (NYSE:BRO) closed at $69.27 per share, reflecting a market capitalization of $23.48 billion. Brown & Brown, Inc. (NYSE:BRO) posted a one-month return of 15.10%, while its shares lost 35.94% over the past 52 weeks.
Artisan Mid Cap Value Fund stated the following regarding Brown & Brown, Inc. (NYSE:BRO) in its Q1 2026 investor letter:
"We initiated six new positions in Q1, representing an above-average rate of new purchase activity. Increased market volatility and greater dispersion in US equities during the quarter created more opportunities to add new names that meet our three margin-of-safety criteria: attractive business economics, sound financial condition and attractive valuation. Additionally, we sought to use recent volatility to upgrade the portfolio's quality. Our three largest new buys by position size were Brown & Brown, Inc. (NYSE:BRO), Veralto and IQVIA Holdings.
Brown & Brown is a leading US insurance broker focused on the middle market. The shares have come under pressure alongside the broader broker group, as investors recalibrated expectations following a period of elevated growth driven by a hard insurance market. As pricing and growth have begun to normalize, valuations have compressed, creating what we believe is a more attractive entry point. From a business economics perspective, insurance brokerage is a compelling model. Brokers act as intermediaries without taking underwriting risk, resulting in high margins, low capital intensity and strong free cash flow conversion, supported by high customer retention. Brown & B

Artisan Partners, an investment management firm, issued its first-quarter 2026 investor letter for the "Artisan Mid Cap Value Fund". A copy of this letter is available for download here. In Q1 2026, the portfolio underperformed the benchmark Russell Midcap Value Index as the market favored momentum-driven stocks over quality factors. Some holdings faced company-specific setbacks and negative sentiment. The Fund's Investor Class: ARTQX returned -4.93%, Advisor Class: APDQX declined by -4.90%, and Institutional Class: APHQX fell by -4.97%, all trailing the Index's 3.68% gain. The equity market in the quarter was mixed, with mid- and small-cap indices showing resilience despite lagging large-cap growth stocks. Volatility increased, initially fueled by interest in AI and private credit, but escalated after the outbreak of war in Iran, leading to rising oil prices. Sector performance varied, with energy leading the gains. The Fund continues to seek companies capable of value growth during market dislocations at attractive entry points. Also, review the Fund's top five holdings to see its best picks for 2026.
In its first-quarter 2026 investor letter, Artisan Mid Cap Value Fund highlighted Brown & Brown, Inc. (NYSE:BRO) as a newly added position. Brown & Brown, Inc. (NYSE:BRO) is a leading insurance brokerage firm that operates through Retail and Specialty Distribution segments. On July 7, 2026, Brown & Brown, Inc. (NYSE:BRO) closed at $69.27 per share, reflecting a market capitalization of $23.48 billion. Brown & Brown, Inc. (NYSE:BRO) posted a one-month return of 15.10%, while its shares lost 35.94% over the past 52 weeks.
Artisan Mid Cap Value Fund stated the following regarding Brown & Brown, Inc. (NYSE:BRO) in its Q1 2026 investor letter:
"We initiated six new positions in Q1, representing an above-average rate of new purchase activity. Increased market volatility and greater dispersion in US equities during the quarter created more opportunities to add new names that meet our three margin-of-safety criteria: attractive business economics, sound financial condition and attractive valuation. Additionally, we sought to use recent volatility to upgrade the portfolio's quality. Our three largest new buys by position size were Brown & Brown, Inc. (NYSE:BRO), Veralto and IQVIA Holdings.
Brown & Brown is a leading US insurance broker focused on the middle market. The shares have come under pressure alongside the broader broker group, as investors recalibrated expectations following a period of elevated growth driven by a hard insurance market. As pricing and growth have begun to normalize, valuations have compressed, creating what we believe is a more attractive entry point. From a business economics perspective, insurance brokerage is a compelling model. Brokers act as intermediaries without taking underwriting risk, resulting in high margins, low capital intensity and strong free cash flow conversion, supported by high customer retention. Brown & B

Artisan Partners, an investment management firm, issued its first-quarter 2026 investor letter for the "Artisan Mid Cap Value Fund". A copy of this letter is available for download here. In Q1 2026, the portfolio underperformed the benchmark Russell Midcap Value Index as the market favored momentum-driven stocks over quality factors. Some holdings faced company-specific setbacks and negative sentiment. The Fund's Investor Class: ARTQX returned -4.93%, Advisor Class: APDQX declined by -4.90%, and Institutional Class: APHQX fell by -4.97%, all trailing the Index's 3.68% gain. The equity market in the quarter was mixed, with mid- and small-cap indices showing resilience despite lagging large-cap growth stocks. Volatility increased, initially fueled by interest in AI and private credit, but escalated after the outbreak of war in Iran, leading to rising oil prices. Sector performance varied, with energy leading the gains. The Fund continues to seek companies capable of value growth during market dislocations at attractive entry points. Also, review the Fund's top five holdings to see its best picks for 2026.
In its first-quarter 2026 investor letter, Artisan Mid Cap Value Fund highlighted Veralto Corporation (NYSE:VLTO) as a newly added position. Veralto Corporation (NYSE:VLTO) is an industrial technology company specializing in water **** ytics, water treatment, marking and coding, and packaging and color solutions. On July 7, 2026, Veralto Corporation (NYSE:VLTO) closed at $93.10 per share, reflecting a market capitalization of $22.86 billion. Veralto Corporation (NYSE:VLTO) posted a one-month return of 12.68%, while its shares lost 9.06% over the past 52 weeks.
Artisan Mid Cap Value Fund stated the following regarding Veralto Corporation (NYSE:VLTO) in its Q1 2026 investor letter:
"We initiated six new positions in Q1, representing an above-average rate of new purchase activity. Increased market volatility and greater dispersion in US equities during the quarter created more opportunities to add new names that meet our three margin-of-safety criteria: attractive business economics, sound financial condition and attractive valuation. Additionally, we sought to use recent volatility to upgrade the portfolio's quality. Our three largest new buys by position size were Brown & Brown, Veralto Corporation (NYSE:VLTO) and IQVIA Holdings.
Veralto is a provider of water quality and product quality solutions that was spun out of Danaher in 2023. The shares have traded off from prior levels and now reflect more modest expectations, creating an opportunity to invest in a historically high-quality compounder at a more reasonable valuation. The company's conservative guidance for full-year EPS disappointed the market. From a business economics perspective, Veralto benefits from attractive end markets and durable competitive advantages. Its Water Quality and Product Quality & Innovation segments operate in niches characterized by high regulatory requirements,

Artisan Partners, an investment management firm, issued its first-quarter 2026 investor letter for the "Artisan Mid Cap Value Fund". A copy of this letter is available for download here. In Q1 2026, the portfolio underperformed the benchmark Russell Midcap Value Index as the market favored momentum-driven stocks over quality factors. Some holdings faced company-specific setbacks and negative sentiment. The Fund's Investor Class: ARTQX returned -4.93%, Advisor Class: APDQX declined by -4.90%, and Institutional Class: APHQX fell by -4.97%, all trailing the Index's 3.68% gain. The equity market in the quarter was mixed, with mid- and small-cap indices showing resilience despite lagging large-cap growth stocks. Volatility increased, initially fueled by interest in AI and private credit, but escalated after the outbreak of war in Iran, leading to rising oil prices. Sector performance varied, with energy leading the gains. The Fund continues to seek companies capable of value growth during market dislocations at attractive entry points. Also, review the Fund's top five holdings to see its best picks for 2026.
In its first-quarter 2026 investor letter, Artisan Mid Cap Value Fund highlighted IQVIA Holdings Inc. (NYSE:IQV). IQVIA Holdings Inc. (NYSE:IQV) is a US-based provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries. On July 7, 2026, IQVIA Holdings Inc. (NYSE:IQV) closed at $208.23 per share, reflecting a market capitalization of $34.75 billion. IQVIA Holdings Inc. (NYSE:IQV) posted a one-month return of 14.31%, and its shares gained 28.52% over the past 52 weeks.
Artisan Mid Cap Value Fund stated the following regarding IQVIA Holdings Inc. (NYSE:IQV) in its Q1 2026 investor letter:
"We initiated six new positions in Q1, representing an above-average rate of new purchase activity. Increased market volatility and greater dispersion in US equities during the quarter created more opportunities to add new names that meet our three margin-of-safety criteria: attractive business economics, sound financial condition and attractive valuation. Additionally, we sought to use recent volatility to upgrade the portfolio's quality. Our three largest new buys by position size were Brown & Brown, Veralto andIQVIA Holdings Inc. (NYSE:IQV).
IQVIA combines a leading global contract research organization (CRO) franchise with a unique, mission-critical health care data ***** et, creating a diversified model with both cyclical and recurring revenue streams. We believe its Technology & ***** ytics Solutions segment—anchored by proprietary prescription and patient data—provides a durable competitive moat, deeply embedded in pharma workflows, while the CRO business benefits from scale, long-term outsourcing trends and complex trial demand. From a business quality perspective, IQVIA has generated substantial free cash flow and maintained strong competitive positioning, supported by high cust

Hardman Johnston Global Advisors, an investment management firm, issued its investor letter for the Hardman Johnston Large Cap Equity Strategy for the first quarter of 2026. A copy of the letter can be downloaded here. The strategy achieved a return of 0.68% (gross) and 0.57% (net) during this period, in contrast to a -4.33% return for the S&P 500 Total Return Index. Companies with robust backlogs of customer business were rewarded, while those with more economically sensitive clients faced underperformance. Looking beyond the immediate disruptions, the firm believes the overall outlook for the U.S. economy remains positive. Please review the Strategy's top five holdings to gain insights into their key selections for 2026.
In its first-quarter 2026 investor letter Hardman Johnston Large Cap Equity Strategy highlighted IQVIA Holdings Inc. (NYSE:IQV). IQVIA Holdings Inc. (NYSE:IQV) is a US-based provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries. On July 1, 2026, IQVIA Holdings Inc. (NYSE:IQV) closed at $203.20 per share, reflecting a market capitalization of $33.91 billion. IQVIA Holdings Inc. (NYSE:IQV) posted a one-month return of 8.73%, and its shares gained 23.72% over the past 52 weeks.
Hardman Johnston Large Cap Equity Strategy stated the following regarding IQVIA Holdings Inc. (NYSE:IQV) in its Q1 2026 investor letter:
"Also detracting was IQVIA Holdings Inc. (NYSE:IQV). A critical partner to the biotech and pharmaceutical industries, the stock has been under pressure from both fears of AI disruption (they argue that it will help both them and their customers) and a turn-up in interest rates slowing spending for some of their smaller customers. While there may be something to the second point, we continue to think that the collection of capabilities and **** ets this company holds makes them a powerful player in their industry."
IQVIA Holdings Inc. (NYSE:IQV) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 64 hedge fund portfolios held IQVIA Holdings Inc. (NYSE:IQV) at the end of the first quarter, compared to 69 in the previous quarter. While we acknowledge the potential of IQVIA Holdings Inc. (NYSE:IQV) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.